

Particles and Health 2021

London, UK

Opening Comments

Robert J. McCunney, MD, MPH, MS

Conference Director

October 20, 21, 2021

Welcome

Background. Upwards of 250 enrollees

Purpose: present current scientific information on particles and health regarding risks to human health and the environment.

Address

1. Uncertainties of defining poorly soluble low toxicity particles (PSLTs).
2. Whether PSLTs should be considered separate entities or broadly defined?
3. Appropriate regulatory applications of the health related science of PSLTs?

Note: Program and web site includes additional details of background and goals of the conference

Conference Structure: 4 Major Sections

1. Human Studies: Role of human studies, including epidemiology, in assessing health risk

2. Animal Studies:

- Inflammation as a key adverse outcome pathway in particle induced effects
- Challenges provided by GHS based target organ toxicity-design and interpretation of inhalation studies of new and existing materials

3. Nanoparticle toxicology -Non-pulmonary effects

4. Regulatory application of Science

Luncheon presentations on “Medical Publishing today” and “Microplastics”

- Each section followed by a panel to address questions and comments
- Presentations will remain on conference web site for 90 days and will be submitted for peer review and publication in “Frontiers in Public Health”

Thank you

- Academic Sponsor: Institute of Occupational Medicine, Edinburgh, Scotland; Nathan Baker, Executive Director
- Conference Moderators: Paul Borm, PhD; Kevin Driscoll, PhD; Len Levy, PhD and Nils Krueger, DVM, PhD.
- Panelists: Robert Blink, MD; Alison Elder, PhD; Annie Jarabek, PhD; Tim Bowmer, Alick Morris, Paul Schulte, PhD
- Conference Coordinator: Amy Cawthan, Venues and Solutions, UK; and Drew Holmes, AV Matrix, UK.
- Financial Support: International Carbon Black Association (ICBA), Association of Amorphous Silica Producers (ASASP) and Synthetic Amorphous Silica and Silicate Industry Association (SASSI)

Human Studies

Theme: Role of human studies, including epidemiology, in assessing health risk

Health Section

1. IOM and particles: a long history in research and service in protecting human health. Nathan Baker; Executive Director of IOM

2. Role of epidemiology in human risk assessment. Ken Mundt, PhD

3. Carbon Black and Lung Cancer Mortality —A Meta regression Analysis Based on Three Occupational Cohort Studies. Mei Yong, MD, PhD

Break

Health Section

4. Is coal a surrogate for a poorly soluble particles?

- Robert McCunney, MD, MPH

5. PSLT's & Lung Function and Malignancy: Causal Inference Analysis

- Philip Harber, MD, MPH

6. Pulmonary Inflammation, asthma and exhaled nitric oxide

- Chris Fanta, MD

Panel Discussion. Robert Blink, MD, MPH and Robert McCunney, MD, MPH